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As one of the major complication of liver cirrhosis, 
portal hypertensive gastropathy (PHG) should be an 
interesting topic to study. Until now the exact mechanism 
on how this phenomenon happened is yet, not clear.1 The 
occurrence of PHG is quite high in patient liver cirrhosis 
and some relationship occurred between PHG and portal 
hypertension. In liver cirrhosis patients, PHG may be 
closely associated with hepatic vein pressure gradient 
(HVPG).2 However, PHG may not be directly associated 
with portal pressure because the mucosal damage not 
linearly correlated with portal hypertension, hence other 
mechanism involved in the etiopathogenesis of PHG.1 
In this regards, the most important factor related to PHG 
is the pressure in the splanchnic vasculature. Based 
on histopathology study in PHG, vascular congestion 
resulted from increased portal pressure reduced oxygen 
for gastric mucosa, hence exposed mucosal layer to 
irritants.2 Moreover, the congestion somehow increased 
the production of nitric oxide, either through the shear 
stress locally or as the result of increase production of 
splanchnic vasculature due to portal hypertension.This 
condition of increased oxidative stress ingastic mucosa 
mostly because of increase production of radical oxygen 
species and decrease production of tissue anti-oxidant 
such as glutathione synthetase and super oxide dismutase 
(SOD).Our study (unpublished) along with other have 
shown that oxidative stress play a role in PHG and anti-
oxidant reduced the gastric mucosal damage. It is not 
clear whether gastric mucosal damage is due to increased 
susceptibility or related to increased of portal pressure. 
Patients with liver cirrhosis may not produce enough 
prostaglandin that needed by the mucosa as protection.2 In 
this regard, mucosal damage in PHG may be the results of 
metabolic activity in local condition rather than merely an 
increased susceptibility of the mucosa for noxious agents. 
In line with this, the portal hypertension it self may be not 
VXI¿FLHQWHQRXJKWRGDPDJHWKHJDVWULFPXFRVDDQGOLYHU
dysfunction also play important part in pathogenesis of 
PHG. In PHG, acid secretion, both basal and stimulated 
secretion is reduced that may have relation with cirrhosis 
and portal hypertension.2
With all the complexity in the pathogenesis of PHG, 
changes in gastric pH and it consequences may not 
be easily understood. Rohmat et al in this publication 
showed that gastric pH increased along with severity 
of PHG.4 They concluded that gastric pH is very likely 
an attempt to protect gastric mucosal damage. We 
know that gastric pH will be increased along with the 
decline in liver function. The mechanism regarding this 
condition not properly understood but may be related 
to the decline in the productions of proteins (enzymes 
or co-factors) that impaired along with declining of 
liver function. As such, the production of gastric acid 
also impaired. Whether increased of gastric pH will 
be protective to mucosa may be need further study. 
However, Rohmat et al were able to show that in liver 
cirrhosis patients, gastric pH can be increased without 
any intervention such as proton pump inhibitor.4 This 
situation should also challenge the use of medications 
that can increase gastric pH. The use of proton pump 
inhibitor (PPI) that is quite frequently given to liver 
cirrhosis patients largely put into question. In PHG the 
XVHRI33,GRHVQRWVKRZHGDQ\HI¿FDF\DQGVWDQGDUG
treatment will be the use of non-selective beta-blocker 
(NSB).1,5 +RZHYHUWKHHI¿FDF\RI16%LQ3+*RQO\
SDUWRIWKHVROXWLRQEHFDXVHVWLOOVLJQL¿FDQWQXPEHUV
of patients have mucosal damage besides the usage of 
effective NSB. Changes in gastric pH as a consequence 
of to protect the gastric mucosa in PHG should be 
considered a passive event rather that active defense 
mechanism. 
6HYHUDOFODVVL¿FDWLRQVIRU3+*KDYHEHHQSURSRVHG
Rohmat et al, determined the degree of mucosal 
damage of PHG based on McCormack study while the 
other one were proposed by the New Italian Endoscopy 
Club (NIEC) and Baveno III.6 ,Q1,(&FODVVL¿FDWLRQ
WKHULVNRIEOHHGLQJZDV±LQPLOG3+*DQG
± LQ VHYHUH 3+*1 Severe PHG reported by 
5RKPDWHWDOLQWKLVSXEOLFDWLRQZDVWKDWVKRXOG
makes every clinician aware that more than half of 
their patients have a major risk of bleeding because of 
PHG. Clinical presentation of PHG commonly not in 
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the form of profuse bleeding but in chronic blood loss 
and because of it, in liver cirrhosis patients, severe PHG 
should be consider as one condition related to anemia, 
if any. Treatment with NSB should be evaluated with 
cautioned. 5
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